Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for

Proteomics - Clinical Applications

Volumn 5, Issue 5-6, 2011, Pages 233-240

  Spasovski, Goce ^a   Ortiz, Alberto ^b   Vanholder, Raymond ^c   El Nahas, Meguid ^d  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Biomarkers; Cardiovascular disease; Chronic kidney disease; Urine

Indexed keywords

PROTEOME;

CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; DYSLIPIDEMIA; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MICROALBUMINURIA; OBESITY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEINURIA; PROTEOMICS; REVIEW; SMOKING;

BIOLOGICAL MARKERS; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; PHYSICIANS; PROGNOSIS; PROTEOMICS;

EID: 79957601375     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000150     Document Type: Review

References (55)

1. Foley, R. N., Parfrey, P. S., Sarnak, M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998, 32, S112-S119.
2. Barsoum, R. S., Chronic kidney disease in the developing world. N. Engl. J. Med. 2006, 354, 997-999.
3. Zoccali, C., Kramer, A., Jager, K. J., Epidemiology of CKD in Europe: an uncertain scenario. Nephrol. Dial. Transplant. 2010, 25, 1731-1733.
4. Smith, D. H., Gullion, C. M., Nichols, G., Keith, D. S., Brown, J. B., Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J. Am. Soc. Nephrol. 2004, 15, 1300-1306.
5. Pontoriero, G., Pozzoni, P., Vecchio, L. D., Locatelli, F., International Study of health care organization and financing for renal replacement therapy in Italy: an evolving reality. Int. J. Health Care Finance Econ. 2007, 7, 201-215.
6. Taal, M. W., Brenner, B. M., Renal risk scores: progress and prospects. Kidney Int. 2008, 73, 1216-1219.
7. Barri, Y. M., Hypertension and kidney disease: a deadly connection. Curr. Cardiol. Rep. 2006, 8, 411-417.
8. El Nahas, M., Bello, A. K., Chronic kidney disease: the global challenge. Lancet 2005, 365, 331-340.
9. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D. C., Coppo, R., Cook, H. T., Feehally, J. et al., The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009, 76, 534-545.
10. National Kidney Foundation, K/DOQI kidney disease outcome quality initiative. Am. J. Kidney Dis. 2002, 39, S1-S266.
11. Coresh, J., Selvin, E., Stevens, L. A., Manzi, J. et al., Prevalence of chronic kidney disease in the United States. J. Am. Med. Assoc. 2007, 298, 2038-2047.
12. Hillege, H. L., Janssen, W. M., Bak, A. A., Diercks, G. F. et al., Prevend study group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J. Intern Med. 2001, 249, 519-526.
13. National Collaborating Centre for Chronic Conditions, Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care, Royal College of Physicians, London 2008.
14. Ruggenenti, P., Perticucci, E., Cravedi, P., Gambara, V. et al., Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 2008, 19, 1213-1224.
15. Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B., Smith, D. H., Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med. 2004, 164, 659-663.
16. Vanholder, R., Massy, Z., Argiles, A., Spasovski, G. et al., European uremic toxin work group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 2005, 20, 1048-1056.
17. Chronic Kidney Disease Prognosis Consortium, Matsushita, K., van der Velde, M., Astor, B. C., Woodward, M. et al., Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375, 2073-2081.
18. Al-Aly, Z., Zeringue, A., Fu, J., Rauchman, M. I. et al., Rate of kidney function decline associates with mortality. J. Am. Soc. Nephrol. 2010, 21, 1961-1969.
19. Zoccali, C., Kramer, A., Jager, K.J., Chronic kidney disease and end-stage renal disease - a review produced to contribute to the report 'the status of health in the European union: towards a healthier Europe'. NDT Plus 2010, 3, 213-224.
20. Levey, A. S., de Jong, P. E., Coresh, J., Nahas, M. E. et al., The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2010, doi:10.1038/ki.2010.483.
21. Eknoyan, G., Chronic kidney disease definition and classification: no need for a rush to judgment. Kidney Int. 2009, 75, 1015-1018.
22. Winearls, C. G., Glassock, R. J., Dissecting and refining the staging of chronic kidney disease. Kidney Int. 2009, 75, 1009-1014.
23. Jerums, G., Panagiotopoulos, S., Premaratne, E., MacIsaac, R. J., Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat. Rev. Nephrol. 2009, 5, 397-406.
24. USRD Report on ESRD,
25. Haroun, M. K., Jaar, B. G., Hoffman, S. C., Comstock, G. W. et al., J., Risk factors for chronic kidney disease: a prospective study of 23, 534 men and women in Washington County, Maryland. J. Am. Soc. Nephrol. 2003, 14, 2934-2941.
26. Murea, M., Freedman, B. I., Essential hypertension and risk of nephropathy: a reappraisal. Curr. Opin. Nephrol. Hypertens. 2010, 19, 235-241.
27. Haubitz, M., Wittke, S., Weissinger, E. M., Walden, M. et al., Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005, 67, 2313-2320.
28. Polanco, N., Gutiérrez, E., Covarsí, A., Ariza, F. et al., Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 2010, 21, 697-704.
29. Waldman, M., Austin, H.A., 3rd, Controversies in the treatment of idiopathic membranous nephropathy. Nat. Rev. Nephrol. 2009, 5, 469-479.
30. Torres, V. E., Treatment strategies and clinical trial design in ADPKD. Adv. Chronic Kidney Dis. 2010, 17, 190-204.
31. Strippoli, G. F., Craig, J. C., Schena, F. P., The number, quality, and coverage of randomized controlled trials in nephrology. J. Am. Soc. Nephrol. 2004, 15, 411-419.
32. Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L. et al., (ONTARGET investigators). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372, 547-553.
33. Walz, G., Budde, K., Mannaa, M., Nuernberger, J. et al., Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2010, 363, 830-840.
34. O'Seaghdha, C. M., Fox, C. S., Genetics of chronic kidney disease. Nephron Clin. Pract. 2011, 118, c55-c63.
35. Price, P. M., Hirschhornm, K., Safirsteinm, R. L., Chronic kidney disease and GWAS: "the proper study of mankind is man". Cell Metab. 2010, 11, 451-452.
36. Lemley, K. V., An introduction to biomarkers: applications to chronic kidney disease. Pediatr. Nephrol. 2007, 22, 1849-1859.
37. Hurst, R. E., Does the biomarker search paradigm need re-booting? BMC Urol. 2009, 9, 1.
38. Kitano, H., Systems biology: a brief overview. Science 2002, 295, 1662-1664.
39. Dominiczak, A. F., Herget-Rosenthal, S., Delles, C., Fliser, D. et al., Systems biology to battle vascular disease. Nephrol. Dial. Transplant. 2010, 25, 1019-1022.
40. Molina, F., Dehmer, M., Perco, P., Graber, A. et al., Systems biology: opening new avenues in clinical research. Nephrol. Dial. Transplant. 2010, 25, 1015-1018.
41. Friedrich-Rust, M., Rosenberg, W., Parkes, J., Herrmann, E. et al., Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010, 10, 103-110.
42. Fliser, D., Novak, J., Thongboonkerd, V., Argiles, A. et al., Advances in urinary proteome analysis and biomarker discovery. J. Am. Soc. Nephrol. 2007, 18, 1057-1071.
43. Mischak, H., Apweiler, R., Banks, R. E., Conaway, M. et al., Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 2007, 1, 148-156.
44. Mischak, H., Allmaier, G., Apweiler, R., Attwood, T. et al., Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. Sci. Transl. Med. 2010, 2, 46ps42.
45. Coon, J. J., Zürbig, P., Dakna, M., Dominiczak, A. F. et al., CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl. 2008, 2, 964-973.
46. Alkhalaf, A., Zurbig, P., Bakker, S. J., Bilo, H. J. et al., Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010, 5, e13421.
47. Rossing, K., Mischak, H., Dakna, M., Zürbig, P. et al., Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 2008, 19, 1283-1290.
48. Andersen, S., Mischak, H., Zürbig, P., Parving, H. H., Rossing, P., Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol. 2010, 11, 29.
49. Good, D. M., Zürbig, P., Argilés, A., Bauer, H. W. et al., Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics 2010, 9, 2424-2437.
50. Rossing, K., Mischak, H., Rossing, P., Schanstra, J. P. et al., The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin. Appl. 2008, 2, 997-1007.
51. Hewitt, S. M., Dear, J., Star, R. A., Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 2004, 15, 1677-1689.
52. Julian, B. A., Suzuki, H., Spasovski, G., Suzuki, Y. et al., Application of proteomic analysis to renal disease in the clinic. Proteomics Clin. Appl. 2009, 3, 1023-1028.
53. de Zeeuw, D., Lewis, E. J., Remuzzi, G., Brenner, B. M. et al., Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006, 367, 899-900.
54. Vlahou, A., Schanstra, J., Frokiaer, J., El Nahas, M. et al., Establishment of a European network for urine and kidney proteomics. J. Proteomics 2008, 71, 490-492.
55. Rossing, K., Mischak, H., Parving, H. H., Christensen, P. K. et al., Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int. 2005, 68, 193-205.